{"disease":{"id":"kidney","name":"kidney"},"drugs":{"marketed":[{"drug_id":"dapagliflozin","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"cyclosporine","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"cyclosporine","company_name":"Novartis AG (originally Sandoz)","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"Calcineurin inhibitor (immunosuppressant)","quality_score":67,"revenue":"1866.0","mechanism":"Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection."},{"drug_id":"ciclosporin","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"Ciclosporin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform","drug_class":"Calcineurin Inhibitor Immunosuppressant [EPC]","quality_score":68,"revenue":"1866.0","mechanism":""},{"drug_id":"tacrolimus","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"tolvaptan","indication_name":"Polycystic kidney disease, adult type","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Samsca","generic_name":"TOLVAPTAN","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Vasopressin V2 receptor","drug_class":"Vasopressin V2 Receptor Antagonist [EPC]","quality_score":80,"revenue":"1200","mechanism":"Samsca works by blocking the action of vasopressin, a hormone that regulates water levels in the body."},{"drug_id":"canagliflozin","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invokana","generic_name":"CANAGLIFLOZIN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":71,"revenue":"800","mechanism":"Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption."},{"drug_id":"finerenone","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kerendia","generic_name":"FINERENONE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]","quality_score":59,"revenue":"600","mechanism":"Kerendia works by blocking the mineralocorticoid receptor, a protein that regulates sodium and potassium levels in the body."},{"drug_id":"roxadustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evrenzo","generic_name":"ROXADUSTAT","company_name":"Astellas Pharma Europe B.V.","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor beta","drug_class":"","quality_score":35,"revenue":"600","mechanism":""},{"drug_id":"everolimus","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"everolimus","indication_name":"Angiomyolipoma of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"epoetin-alfa","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"EPOETIN ALFA","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating Agent","quality_score":63,"revenue":"400","mechanism":"Epogen works by binding to the erythropoietin receptor, triggering a cascade of signals that stimulate the production of red blood cells."},{"drug_id":"retacrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"Epoetin Alfa-Epbx","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":"400","mechanism":"Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"methoxy-polyethylene-glycol-epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mircera","generic_name":"METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"erythropoietin receptor","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Mircera activates erythropoietin receptors, increasing red cell production in response to hypoxia."},{"drug_id":"epogen","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epogen","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic kidney disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"mycophenolate","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mycophenolate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 1, Inosine-5'-monophosphate dehydrogenase 2, Inosine-5'-monophosphate dehydrogenase (IMPDH)","drug_class":"","quality_score":42,"revenue":null,"mechanism":null},{"drug_id":"procrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Procrit","company_name":"University of Louisville","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"endometrin","indication_name":"Secondary malignant neoplasm of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Angiomyolipoma of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imlifidase","indication_name":"Transplant of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ides","generic_name":"IMLIFIDASE","company_name":"Hansa Biopharma AB","drug_phase":"marketed","molecular_target":"Immunoglobulin gamma (IgG), heavy chain","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"ciclosporine","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ciclosporine","company_name":"Hospices Civils de Lyon","drug_phase":"phase_3","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"erythropoietin","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erythropoietin","company_name":"Nanjing First Hospital, Nanjing Medical University","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"dapa","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"mycophenolate-mofetil","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cellcept","generic_name":"MYCOPHENOLATE MOFETIL","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":"Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides."},{"drug_id":"valganciclovir","indication_name":"Prevention of CMV Disease After Kidney Transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valcyte","generic_name":"VALGANCICLOVIR","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor."},{"drug_id":"valganciclovir","indication_name":"Prevention of CMV Disease After Kidney-Pancreas Transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valcyte","generic_name":"VALGANCICLOVIR","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor."},{"drug_id":"epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neorecormon","generic_name":"EPOETIN BETA","company_name":"Roche Registration Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Neorecormon works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production."},{"drug_id":"olmesartan","indication_name":"diabetic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"mycophenolic-acid","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycophenolate","generic_name":"MYCOPHENOLIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hctz","indication_name":"diabetic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"anti-thymocyte-globulin","indication_name":"Prophylaxis and treatment of acute rejection in kidney transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Anti Thymocyte Globulin","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"Immunoglobulin G [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Prevention of CMV Disease After Kidney Transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"ganciclovir","indication_name":"Prevention of CMV Disease After Kidney-Pancreas Transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"sirolimus","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapamune","generic_name":"sirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"mTOR Inhibitor Immunosuppressant [EPC]","quality_score":80,"revenue":null,"mechanism":"Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells."},{"drug_id":"sotagliflozin","indication_name":"Chronic kidney disease at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"forxiga","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neoral","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neoral","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cyclosporin","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclosporin","company_name":"Karolinska University Hospital","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"progesteron","indication_name":"Secondary malignant neoplasm of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mircera","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mircera","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rapamycin","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamycin","company_name":"Institut National de la Santé Et de la Recherche Médicale, France","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neorecormon","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neorecormon","company_name":"Centre Hospitalier Universitaire, Amiens","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"celery-seed","indication_name":"Kidney stones","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Celery Seed","company_name":"University of Guadalajara","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"furosemide-injection","indication_name":"Edema in adults with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"enarodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enaroy","generic_name":"ENARODUSTAT","company_name":"Japan Tabacco","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"dapaglifozin","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"daprodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jesduvroq","generic_name":"DAPRODUSTAT","company_name":"GSK","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production."},{"drug_id":"rapamune","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamune","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"azathioprine","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"medroxyprogesterone","indication_name":"Secondary malignant neoplasm of kidney","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"nandrolone-decanoate","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nandrolone Decanoate","generic_name":"NANDROLONE DECANOATE","company_name":"Woodward Specl","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"difelikefalin","indication_name":"Pruritus associated with chronic kidney disease (CKD-aP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Korsuva","generic_name":"DIFELIKEFALIN","company_name":"Vifor Intl","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"Kappa Opioid Receptor Agonist","quality_score":48,"revenue":null,"mechanism":"Korsuva works by activating the kappa-type opioid receptor, which helps to reduce itching."},{"drug_id":"epoetin-zeta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silapo","generic_name":"EPOETIN ZETA","company_name":"Hospira UK Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"phytonadione","indication_name":"End-stage kidney disease","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"chlorthalidone","indication_name":"Indapamide and chlorthalidone to reduce urine supersaturation for kidney stone prevention","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":66,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT07188545","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23280000,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT05198492","title":"Short- and Long-term Health Effects of Air Pollution in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04053335","title":"Smarter Care Virginia, Examining Low-Value Care in Virginia","phase":"","overall_status":"COMPLETED","enrollment_count":5000000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06239129","title":"The Stockholm CREAtinine Measurements Project","phase":"","overall_status":"COMPLETED","enrollment_count":3200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05932901","title":"OPTIMISE-CKD Drug Utilization","phase":"","overall_status":"COMPLETED","enrollment_count":2682052,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03084172","title":"Systemic Redesign and Demonstration for Early Detection, Evaluation and Management of Chronic Kidney Disease in Shanghai","phase":"","overall_status":"UNKNOWN","enrollment_count":2000000,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT04847531","title":"REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":1006361,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05914259","title":"An Observational Study to Learn More How Chronic Kidney Disease Gradually Changes Over Time in Adults Using Electronic Healthcare Records (CKD Natural History Study)","phase":"","overall_status":"COMPLETED","enrollment_count":969394,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05813652","title":"Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1","phase":"","overall_status":"COMPLETED","enrollment_count":919928,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT05953701","title":"Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics","phase":"","overall_status":"COMPLETED","enrollment_count":800211,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04417725","title":"Burden of Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), and Comorbid T2DM/CKD in Alberta, Canada","phase":"","overall_status":"COMPLETED","enrollment_count":588170,"lead_sponsor_name":"Medlior Health Outcomes Research Ltd","has_results":false},{"nct_id":"NCT02695082","title":"Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications","phase":"","overall_status":"COMPLETED","enrollment_count":539310,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07465926","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","phase":"","overall_status":"COMPLETED","enrollment_count":451036,"lead_sponsor_name":"Chung Shan Medical University","has_results":false},{"nct_id":"NCT05986474","title":"Development of Synthetic Medical Data Generation Technology to Predict Postoperative Complications","phase":"","overall_status":"COMPLETED","enrollment_count":410000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05004428","title":"A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)","phase":"","overall_status":"COMPLETED","enrollment_count":336376,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06898944","title":"Prognosis and Risk Factors for Acute Kidney Injury","phase":"","overall_status":"RECRUITING","enrollment_count":320000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06330480","title":"Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":320000,"lead_sponsor_name":"Prof. Dr. Folkert W. Asselbergs","has_results":false},{"nct_id":"NCT07080086","title":"The Effect of Preoperative Biological Age on Hemodynamics and Renal Function","phase":"","overall_status":"COMPLETED","enrollment_count":268833,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT05248412","title":"The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07093684","title":"Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03807648","title":"I USE LR in the ED","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Intermountain Health Care, Inc.","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT03958760","title":"Characteristics, Treatment, and Economic Burden of Patients With CVD,CKD or at High Cardiovascular Risk","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06840210","title":"Effectiveness-Implementation Evaluation of Acute Kidney Injury Decision Support","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT05050877","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention II","phase":"","overall_status":"COMPLETED","enrollment_count":184855,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT03353389","title":"Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang","phase":"","overall_status":"COMPLETED","enrollment_count":170000,"lead_sponsor_name":"Selayang Hospital","has_results":false},{"nct_id":"NCT06608212","title":"An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06769646","title":"SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data","phase":"","overall_status":"COMPLETED","enrollment_count":110074,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05526599","title":"The Association of Marital Status With Kidney Cancer Surgery Morbidity","phase":"","overall_status":"COMPLETED","enrollment_count":106752,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT07365111","title":"Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT00342927","title":"Family Investigation of Nephropathy and Diabetes (F.I.N.D.)","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT07128966","title":"Direct to Patient Minimal Risk Biospecimen and Data Collection Research","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Joined Bio","has_results":false},{"nct_id":"NCT04302974","title":"Cohort Study on Patient Outcomes, Effectiveness and Cost-effectiveness of Intervention Programmes for DM/HT Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03723668","title":"Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France","phase":"","overall_status":"COMPLETED","enrollment_count":94017,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT03185598","title":"MACE and First Operating Room Systolic Blood Pressure in Patients Undergoing Non-cardiac Surgery Implications for the Hypertension Threshold","phase":"","overall_status":"COMPLETED","enrollment_count":90342,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT05188885","title":"A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":90000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04407936","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention","phase":"","overall_status":"COMPLETED","enrollment_count":88938,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06146829","title":"Machine Learning Models for Prediction of Acute Kidney Injury After Noncardiac Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":88367,"lead_sponsor_name":"Rao Sun","has_results":false},{"nct_id":"NCT04882813","title":"Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":87727,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05530291","title":"Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":85259,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05225454","title":"The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques","phase":"","overall_status":"UNKNOWN","enrollment_count":81108,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT03954353","title":"Effect of Cholesterol Level on Postoperative Acute Kidney Injury of Non-cardiac Surgeries","phase":"","overall_status":"COMPLETED","enrollment_count":78888,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT02402244","title":"Project: Every Child for Younger Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06531629","title":"Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":72408,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT05151003","title":"Epidemiology of In-hospital Acute Kidney Injury","phase":"","overall_status":"UNKNOWN","enrollment_count":60000,"lead_sponsor_name":"Universita degli Studi di Genova","has_results":false},{"nct_id":"NCT06462755","title":"Perioperative Database of Chinese Elderly Patients for Postoperative Acute Kidney Injury","phase":"","overall_status":"COMPLETED","enrollment_count":57089,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07317817","title":"Research on Risk Assessment and Early Warning Models for Adverse Clinical Outcomes in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":55940,"lead_sponsor_name":"Chongqing Medical University","has_results":false},{"nct_id":"NCT07217535","title":"Rutgers University Study of the Genetics of Kidney Disease","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT03629977","title":"Timing of Renal Replacement Therapy in the Critically Ill Patients","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Karolinska University Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}